Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.

Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024) is scheduled for September 4-7, 2024 at the GRB Convention Center in Houston, Texas. As a hybrid event, SOHO 2024 offers in-person, virtual and on-demand participation.

Register Now
  • 7,752 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

What Is the Benefit of Blinatumomab in MRD-Positive B-Cell ALL

53.8% of patients treated with blinatumomab achieved MRD negativity within a median of 3.1 months, as detected with clonoSEQ.

Adding Elotuzumab to Triplet Therapy Provides ‘No Clinical Benefit’ in Newly Diagnosed Myeloma

Adding elotuzumab to induction, consolidation, or maintenance treatment did not result in improved PFS or OS.

Is Ibrutinib Plus Venetoclax Therapy Guided by MRD Effective in CLL

MRD-directed ibrutinib plus venetoclax therapy improved PFS in patients with CLL.

Study Identifies Key Challenges, Needs Among CAR-T Therapies for MM

The study used public data from various online sources related to approved CAR-T therapies for MM.

What Is the Best Timing for CAR-T Treatment in Patients With LBCL

Patients with LBCL who received CAR T-cell therapy earlier in treatment had lower occurrences of severe neutropenia.

Novel Therapy Holds Promise for Patients With BTK Inhibitor-Resistant CLL

NX-2127, a first-in-class therapy, induced BTK degradation and clinical responses in CLL resistant to BTK inhibitors.

FDA Approves Biweekly Dosing for Teclistamab in Relapsed or Refractory Myeloma

The sBLA was approved for a reduced dosing frequency of 1.5 mg/kg every two weeks in relapsed or refractory myeloma.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top